{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:54:57Z","timestamp":1787007297707,"version":"build-2736575974"},"reference-count":127,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2021,10,2]]},"DOI":"10.1080\/14728214.2021.2011858","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T18:13:55Z","timestamp":1638296035000},"page":"401-413","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["Emerging therapies for dry eye disease"],"prefix":"10.1080","volume":"26","author":[{"given":"Lauren","family":"Mason","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Jafri","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Dortonne","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John D","family":"Sheppard","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.289"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.12.023"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1097\/NHH.0000000000000652"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.11.008"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2018.048"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181f7f363"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.003"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2018.12.000047"},{"issue":"9","key":"cit0009","first-page":"Cd010051","volume":"9","author":"de Paiva CS","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2016.96"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1407936"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000721"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.838557"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"cit0015","first-page":"Cd009729","volume":"2","author":"Pucker AD","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23760"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.07.022"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.08.018"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00033"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091439"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000042"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2020.05.009"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000666"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100842"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)00176-1"},{"key":"cit0026","unstructured":"Cequapro.com [Internet]. CEQUA [package insert]. Cranbury (NJ): Sun Pharmaceutical Industries, Inc; 2018 [cited 2021 Feb 17]. Available from: https:\/\/cequapro.com\/dosing"},{"key":"cit0027","unstructured":"Cequapro.com [Internet]. Highlights of prescribing information. Cranbury (NJ): Sun Pharma Global FZE; 2019 [cited 2021 Jun 23]. Available from: https:\/\/cequapro.com\/pdf\/CequaPI.pdf"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S279364"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000636"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2017.03.006"},{"key":"cit0031","unstructured":"Allergan.com [Internet]. Highlights of prescribing information. Irvine (CA): Allergan; 2017 [cited 2021 Jun 23]. Available from: https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/RESTASIS_pi.pdf"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S115098"},{"key":"cit0033","unstructured":"Xiidra-ecp.com [Internet]. Mechanism of Action: xiidra\u00ae (lifitegrast ophthalmic solution) 5%: novartis pharmaceuticals corporation; 2020 [cited 2020 Dec 15]. Available from: https:\/\/www.xiidra-ecp.com\/mechanism-of-action"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.015"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.09.025"},{"key":"cit0036","unstructured":"Globenewswire.com [Internet]. Oyster point pharma submits new drug application to the U.S. Food and drug administration for OC-01. (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease. Oyster Point Pharma, Inc; 2020 [cited 2021 Feb 17]; [about 7 screens]. Available from: https:\/\/www.globenewswire.com\/news-release\/2020\/12\/18\/2147712\/0\/en\/Oyster-Point-Pharma-Submits-New-Drug-Application-to-the-U-S-Food-and-Drug-Administration-for-OC-01-varenicline-Nasal-Spray-for-the-Treatment-of-Signs-and-Symptoms-of-Dry-Eye-Diseas.html"},{"key":"cit0037","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2019 Jul 29 Identifier NCT04036292, evaluating the efficacy and safety of OC-01 (Varenicline) nasal spray on dry eye disease; 2019 Feb 23 [cited 2021 Feb 16]; [about 6 screens]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04036292"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.3390\/nu13010247"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.060"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.01.004"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181f22e03"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.09.023"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1111\/nure.12145"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2018.06.002"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000001884"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000940"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e318299549c"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1492_19"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14470"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2020.03.001"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-313267"},{"issue":"6","key":"cit0052","first-page":"Cd006775","volume":"6","author":"Ervin AM","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"cit0053","first-page":"517","volume":"65","author":"Hart DE","year":"1994","journal-title":"J Am Optom Assoc"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000778"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-23984"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2018.11.002"},{"key":"cit0057","unstructured":"Allergan-web-cdn-prod.azureedge.net [Internet]. TrueTear\u00ae intranasal tear neurostimulator professional information guide pleasanton (CA). Allergan; 2018 [cited 2021 Jun 23]. Available from: https:\/\/allergan-web-cdn-prod.azureedge.net\/actavis\/actavis\/media\/allergan-pdf-documents\/labeling\/ifu_truetear_professional.pdf"},{"issue":"8","key":"cit0058","volume":"58","author":"Dieckmann G","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"cit0059","volume":"58","author":"Pondelis N","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2018.11.009"},{"key":"cit0061","unstructured":"Olympicophthalmics.com [Internet]. iTEAR \u00ae100; 2020 [cited 2021 Feb 14]; [about 2 screens]. Available from: https:\/\/www.olympicophthalmics.com\/devices\/iTEAR100\/"},{"issue":"3","key":"cit0062","first-page":"Cd013559","volume":"3","author":"Cote S","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2019.11.009"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.03.009"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S33133"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997g"},{"key":"cit0067","unstructured":"Karpecki P. Disinfect the natural way. review of optometry [Internet]; 2019. https:\/\/www.reviewofoptometry.com\/article\/disinfect-the-natural-way"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000001621"},{"key":"cit0069","unstructured":"Domp\u00e9 U.S. Inc. Oxervate full prescribing information; 2019."},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2018.04.003"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-16890"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25623"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.08.020"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13907"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.2217\/rme.13.59"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2014.12.027"},{"issue":"4","key":"cit0077","first-page":"29","volume":"2","author":"Kengpunpanich S","year":"2020","journal-title":"J Chulabhorn Royal Acad"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000569"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.011"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.004"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.04.001"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.04.003"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2013.03.005"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1272"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.01.024"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23479"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20303"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2015.11.003"},{"key":"cit0089","first-page":"877","volume":"9","author":"Sosne G","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.001"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.009"},{"key":"cit0092","unstructured":"Adisinsight.springer.com [Internet]. Timbetasin - regenerx biopharmaceuticals Switzerland. \u00a9 Springer Nature; 2021 [updated 2021 Oct 21; cited 2021 Feb17]; [about 3 screens]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800014482"},{"key":"cit0093","unstructured":"Adisinsight.springer.com [Internet]. Loteprednol etabonate transmucosal - Kala pharmaceuticals Switzerland. \u00a9 Springer Nature; 2021 [updated 2021 May 21; cited 2021 Feb 17]; [about 3 screens]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800039532"},{"key":"cit0094","unstructured":"Adisinsight.springer.com [Internet]. Perfluorohexyloctane ophthalmic solution - Novaliq Switzerland. \u00a9 Springer Nature; 2021 [updated 2021 Oct 05; cited 2021 Feb17]; [about 3 screens]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800050602"},{"key":"cit0095","unstructured":"Adisinsight.springer.com [Internet]. Amlisimod - SilkTech biopharmaceuticals Switzerland. \u00a9 Springer Nature; 2021 [updated 2021 May 24; cited 2021 Feb 17]; [about 3 screens]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800054399"},{"key":"cit0096","unstructured":"Adisinsight.springer.com [Internet]. Ciclosporin ophthalmic - Novaliq Switzerland: \u00a9 Springer Nature; 2021 [updated 2021 Sep 23; cited 2021 Feb 17]; [about 3 screens]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800037951"},{"key":"cit0097","unstructured":"Adisinsight.springer.com [Internet]. TOP 1630 Switzerland: \u00a9 Springer Nature; 2020 [updated 2020 Apr 28; cited 2021 Feb 17]; [about 3 screens]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800044911"},{"key":"cit0098","unstructured":"Adisinsight.springer.com [Internet]. Tanfanercept - HanAll Biopharma Switzerland: \u00a9 Springer Nature; 2020 [updated 2021 Aug 04; cited 2021 Feb 17]; [about 4 screens]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800045031"},{"key":"cit0099","unstructured":"Regenerx.com [Internet]. RGN-259: regeneRx; 2020 [cited 2021 Jan 14]; [about 6 screens]. Available from: https:\/\/www.regenerx.com\/RGN-259"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000379"},{"key":"cit0101","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2019 May 6 Identifier NCT03937882, Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3; 2019 May 24 [cited 2020 Dec 22]; [about 4 screens]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03937882"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002452"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0014"},{"key":"cit0104","unstructured":"Sahil A TB. Ocular side-effects of corticosteroids [Internet]. Salt Lake City (UT): Moran Eye Center in partnership with the Eccles Library; [cited 2021 Feb 17]; [about 7 screens]. Available from: http:\/\/morancore.utah.edu\/basic-ophthalmology-review\/ocular-side-effects-of-corticosteroids"},{"key":"cit0105","unstructured":"Businesswire.com [Internet]. Kala pharmaceuticals receives FDA complete response letter for KPI-121 0.25% NDA and plans to respond with data from STRIDE 3 trial. Kala pharmaceuticals, inc; 2019 [cited 2021 Jan 3]; [about 3 screens]. Available from: https:\/\/www.businesswire.com\/news\/home\/20190808005767\/en\/Kala-Pharmaceuticals-Receives-FDA-Complete-Response-Letter-for-KPI-121-0.25-NDA-and-Plans-to-Respond-with-Data-From-STRIDE-3-Trial"},{"key":"cit0106","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 Aug 6 - Identifier NCT03616899, safety and efficacy of KPI-121 in subjects with DED; 2018 Jul 10 [cited 2020 Dec 23]; [about 5 screens]. Available from https:\/\/ClinicalTrials.gov\/show\/NCT03616899;2018."},{"key":"cit0107","unstructured":"Novaliq.com [Internet]. NOV03: novaliq GmbH; 2021 [cited 2021 Jan 3]; [about 3 screens]. Available from: https:\/\/www.novaliq.com\/products\/nov03"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2019.0092"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0048"},{"key":"cit0110","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Nov 6 - Identifier NCT03333057, Perfluorohexyloctane (NOV03) for the treatment of signs and symptoms of dry eye disease (DED); 2018 Jan 3 [cited 2021 Jan 4]; [about 5 screens]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03333057"},{"key":"cit0111","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2019 Oct 25 - Identifier NCT00287391, Perfluorohexylcotane (NOV03) for the treatment of signs and symptoms of dry eye disease associated with meibomian gland dysfunction (Gobi study); 2019 Oct 23 [cited 2021 Jan 4]; [about 5 screens]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04139798"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002622"},{"issue":"9","key":"cit0113","volume":"60","author":"Infanger DW","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188154"},{"key":"cit0115","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2019 Mar 26 - Identifier NCT03889886, study to evaluate the safety and efficacy of SDP-4 in subjects with dry eye disease (DED) (SDP-4-CS201); 2019 Apr 16 [cited 2021 Jan 20]; [about 4 screens]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03889886"},{"key":"cit0116","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2020 Sep 2 - Identifier NCT04535947, Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202); 2020 Aug 14 [cited 2021 Jan 20]; [about 5 screens]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04535947"},{"key":"cit0117","unstructured":"Novaliq.com [Internet]. CyclASol\u00ae: novaliq GmbH; 2021 [cited 2021 Jan 10]. Available from: https:\/\/www.novaliq.com\/products\/cyclasol\/"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S189039"},{"key":"cit0119","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Mar 23 - Identifier NCT03088605, safety and efficacy of TOP1630 for dry eye syndrome; 2017 Feb 20 [cited 2021 Feb 10]; [about 4 screens]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03088605"},{"key":"cit0120","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2019 Feb 7 - Identifier NCT03833388, Study of TOP1630 for Dry Eye Syndrome (THEIA-1); 2019 Feb 13 [cited 2021 Feb 10]; [about 5 screens]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03833388"},{"key":"cit0121","unstructured":"Eyewire.news [Internet]. TopiVert announces topline results from phase 2b\/3 study of dry eye disease drug candidate: Bryn Mawr Communications, LLC; 2019 [cited 2021 Feb 17]; [about 2 screens]. Available from: https:\/\/eyewire.news\/articles\/topivert-announces-topline-results-from-theia-1-phase-2b-3-clinical-study-of-top1630-as-a-treatment-for-dry-eye-disease"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-11515"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2018.1461909"},{"issue":"9","key":"cit0124","volume":"60","author":"Shin M","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0056"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.04.023"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0087"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2021.2011858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T03:05:20Z","timestamp":1654139120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2021.2011858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,2]]},"references-count":127,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10,2]]}},"alternative-id":["10.1080\/14728214.2021.2011858"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2021.2011858","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}